Drugs / ADVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00249106 | Dec 2003 → Oct 2005 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00249106 ↗ |
| Modality | Vaccine | “DNA-based candidate HIV-1 vaccine” PMID 20111582 ↗ Jan 2010 |
| Route | Intramuscular | “ADVAX delivered intramuscularly is safe, well-tolerated, and elicits modest but transient cellular immune responses.” PMID 20111582 ↗ Jan 2010 |